← FDA Drug Approvals (Drugs@FDA)
QTERNMET XR
NDA · New Drug Application · Sponsor: ASTRAZENECA AB · Approved 2019-05-02
Drug application
- FDA Application #
NDA210874- Application type
- New Drug Application
- Brand name
- QTERNMET XR
- Generic name
- Dapagliflozin
- Active ingredients
- DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
- Dosage form
- TABLET, EXTENDED RELEASE
- Route
- ORAL
- Marketing status
- Discontinued
- Sponsor
- ASTRAZENECA AB
- First approval
- 2019-05-02
Source
- Authoritative
- Drugs@FDA application overview
- Machine
- JSON-LD · Markdown